“If we knew what it was we were doing, it would not be called research, would it?” – Albert Einstein
At 9:45 pm tonight, The Myeloma Beacon released an update after receiving a statement from one of the other researchers on another similar though different study utilizing Revlimid. They have also had some concerns regarding the secondary cancer issue and whether it is directly related to the extended use of Revlimid.
I’m very impressed at the late hour the Beacon Staff was working to bring the latest news to its growing readership. Kudos to their dedication. I look forward to hearing more about these latest concerns, but felt somewhat vindicated (at the moment anyway) by my previous statements on, how can you be sure it is coming from the Revlimid?
I’m also grateful to Dr. McCarthy for taking the time to clearly and fully respond to the concerns and questions brought to him by The Myeloma Beacon Staff on behalf of us all. His innate understanding, and sensitivity, that this story would be of grave concern to the thousands of Myeloma patients taking Revlimid in an extended use scenario, is very much appreciated by this humble caregiver.
“…. It is important to remember that multiple myeloma patients, especially those who have received treatment, are at risk for the development of second cancers, so sorting out what is due to a single drug or combination of drugs is very difficult….” – Dr. Philip McCarthy, Lead Investigator, CALGB 100104 trial, Roswell Park Cancer Institute
